Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma

Melanoma Research

Volumn 18, Issue 5, 2008, Pages 346-352

  Singh, Baljinder ^a   Ezziddin, Samer ^b   Palmedo, Holger ^b   Reinhardt, Michael ^c   Strunk, Holger ^b   Tüting, Thomas ^b   Biersack, Hans Jürgen ^b   Ahmadzadehfar, Hojjat ^b,d  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c PIUS HOSPITAL   (Germany)

^d Department of Nuclear Medicine ^*  (Germany)

Author keywords

18F fluorodeoxyglucose positron emission tomography computed tomography; Lymphoscintigraphy; Malignant melanoma; Sentinel lymph node biopsy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOPROMIDE; LYSINE DIATRIZOATE; TECHNETIUM SULFUR COLLOID TC 99M;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MALE; MECHANICAL PROBE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TUMOR LOCALIZATION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 53549107743     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32830b363b     Document Type: Article

References (35)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002; 52:23-47.
2. Weinstock MA. Cutaneous melanoma: public health approach to early detection. Dermatol Ther 2006; 19:26-31.
3. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al., editors. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2004/, based qon November 2006 SEER data submission, posted to the SEER web site 2007.
4. Rompel R, Garbe C, Buttner P, Teichelmann K, Petres J. Elective lymph node dissection in primary malignant melanoma: a matched-pair analysis. Melanoma Res 1995; 5:189-194.
5. Drepper H, Kohler C, Bastian B, Breuninger H, Brocker EB, Gohl J, et al. Benefit of elective lymph node dissection in subgroups of melanoma patients. Cancer 1993; 72:741-749.
6. Voit C, Schoengen A, Schwurzer-voit M, Weber L, Ulrich J, Sterry W, et al. The role of ultrasound in detection and management of regional disease in melanoma patients. Semin Oncol 2000; 7:87-97.
7. Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002; 9:646-653.
8. Morton DL, Chan AD. The concept of sentinel node localization: how it started. Semin Nucl Med 2000; 30:4-10.
9. Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994; 220:759-767.
10. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88:1484-1491.
11. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634.
12. Morton DL, Thompson JF, Essner T, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999; 230:453-463.
13. Cochran AJ, Balda BR, Starz H, Bachter D, Krag DN, Cruse CW, et al. The Augsburg Consensus Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 2000; 89:236-241.
14. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome ML, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience; the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:986-983.
15. Havenga K, Cobben DC, Oyen WJ, Nienhuijs S, Hoekstra HJ, Ruers TJ, et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 2003; 29:662-664.
16. Schoder H, Larson SM, Yeung HWD. PET/CT in oncology: integration into clinical management of lymphoma, melanoma and gastrointestinal malignancies. J Nucl Med 2004; 45:72S-81 S.
17. Belhocine TZ, Scott AM, Even-Sapir E, Urbain JL, Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006; 47:957-967.
18. Vidal-Sicart S, Pons F, Puig S, Ortega M, Vilalta A, Martin F, et al. Identification of the sentinel lymph node in patients with malignant melanoma: what are the reasons for mistakes? Eur J Nucl Med Mol Imaging 2003: 30:362-376.
19. Macfarlane DJ, Schauwecker D, Hutchins G, Wahl RL. Prospective evaluation of 2-(18F)-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998; 16:1770-1776.
20. Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006; 24: 1178-1187.
21. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
22. Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003; 30:588-596.
23. Kinahan PE, Hasegawa BH, Beyer T. X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med 2003; 33:166-179.
24. Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M, et al. Positronemission tomography scanning in malignant melanoma. Cancer 2000;89:1019-1025.
25. Thompson JF, McCarthy WH, Bosch CM, O'Brien CJ, Quinn MJ, Paramaesvaran S, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995; 5:255-260.
26. Joesph E, Brobeil A, Glass F, Glass J, Messina J, DeConti R, et al. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol 1998; 5:119-125.
27. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399.
28. Clary BM, Brady MS, Lewis JJ, Coit DJ. Sentinel lymph node biopsy in themanagement of patients with primary cutaneous melanoma: review of a largesingle-institutional experience with an emphasis on recurrence. Ann Surg 2001; 2:250-258.
29. Acland KM, Healy C, Calonje E, O'Doherty M, Nunan T, Page C, et al. Comparison of positron emission tomography scanning and sentinel lymph node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001; 19:2674-2678.
30. Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P. Staging of regional nodes in AJCC stage I and IE melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist 2002; 7:271-278.
31. Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ III, Hutchins G, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early stage cutaneous melanoma. Cancer 2005; 104:570-579.
32. Clark PB, Soo V, Kraas J, Shen P, Levine EA. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg 2006; 141:284-288.
33. Crippa F, Leutner M, Belli F Gallino F, Greco M, Pilotti S, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000; 41:1491-1494.
34. Wagner JD, Davidson D, Coleman JJ III, Hutchins G, Schauwecker D, Park HM, et al. Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma. Ann Surg Oncol 1999; 6:398-404.
35. Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001; 77:237-242.